ArticleCancer medicine2024

Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors.

Dan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.